Ian is a founder of A4P from its outset in 2011. He is now CEO and supporting both regulatory PK and biomarker groups at A4P. During a subattical, Ian held position as Biomarker Lead in Translational Medicine at UCB responsible for biomarkers in their clinical renal portfolio. Previously prior to A4P, Ian held the position of Diagnostics Director at Pfizer supporting the virology, oncology and emerging diagnostic programmes and prior to that as a Biomarker Lead within the Clinical Assay Group at Pfizer. Ian obtained his PhD from the University of London in 1991.

Since the formation of A4P, Ian has supported various biomarker strategy developments and biomarker implementations for a number of oncology and non oncology programmes at Pharma and Biotech companies and has been instrumental in growing the business and diversifying the talent within A4P to provide broader more comprehensive support for customers.